Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (41-50 of 301) with videos related to

Pageof 31
Sort By:
World Neurosurgery|March 14, 2018
Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case SeriesMathilde Quidet, Fahed Zairi, Eileen Boyle, et al.
Leukemia & Lymphoma|December 29, 2004
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myelomaStephane Depil, Xavier Leleu, Jean-Baptiste Micol, et al.
The Oncologist|April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed MyelomaRafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Blood|March 6, 2002
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentationHervé Avet-Loiseau, Thierry Facon, Bernard Grosbois, et al.
Clinical Hematology International|April 15, 2023
Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)Nizar J Bahlis, Luciano J Costa, Thierry Facon, et al.
Expert Review of Hematology|December 11, 2012
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosisEileen M Boyle, Guillemette Fouquet, Salomon Manier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
British Journal of Haematology|May 27, 2005
Evaluation and prognostic value of serum osteoprotegerin in multiple myelomaStéphane Depil, Claire Mathiot, Xavier Leleu, et al.
Blood|July 20, 2002
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentCatherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, et al.
Biologics : Targets & Therapy|August 27, 2009
Front line treatment of elderly multiple myeloma in the era of novel agentsMarie-Dominique Venon, Aldo M Roccaro, Julie Gay, et al.
Pageof 31

Showing results (41-50 of 301) with videos related to

Sort By:
Pageof 31
World Neurosurgery|March 14, 2018
Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case SeriesMathilde Quidet, Fahed Zairi, Eileen Boyle, et al.
Leukemia & Lymphoma|December 29, 2004
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myelomaStephane Depil, Xavier Leleu, Jean-Baptiste Micol, et al.
The Oncologist|April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed MyelomaRafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Blood|March 6, 2002
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentationHervé Avet-Loiseau, Thierry Facon, Bernard Grosbois, et al.
Clinical Hematology International|April 15, 2023
Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)Nizar J Bahlis, Luciano J Costa, Thierry Facon, et al.
Expert Review of Hematology|December 11, 2012
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosisEileen M Boyle, Guillemette Fouquet, Salomon Manier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
British Journal of Haematology|May 27, 2005
Evaluation and prognostic value of serum osteoprotegerin in multiple myelomaStéphane Depil, Claire Mathiot, Xavier Leleu, et al.
Blood|July 20, 2002
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentCatherine Roche-Lestienne, Valerie Soenen-Cornu, Nathalie Grardel-Duflos, et al.
Biologics : Targets & Therapy|August 27, 2009
Front line treatment of elderly multiple myeloma in the era of novel agentsMarie-Dominique Venon, Aldo M Roccaro, Julie Gay, et al.
Pageof 31